888 reports of this reaction
1.5% of all OXCARBAZEPINE reports
#19 most reported adverse reaction
EPILEPSY is the #19 most commonly reported adverse reaction for OXCARBAZEPINE, manufactured by Novartis Pharmaceuticals Corporation. There are 888 FDA adverse event reports linking OXCARBAZEPINE to EPILEPSY. This represents approximately 1.5% of all 60,018 adverse event reports for this drug.
OXCARBAZEPINE has an overall safety score of 85 out of 100. Patients taking OXCARBAZEPINE who experience epilepsy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPILEPSY is a less commonly reported adverse event for OXCARBAZEPINE, but still significant enough to appear in the safety profile.
In addition to epilepsy, the following adverse reactions have been reported for OXCARBAZEPINE:
The following drugs have also been linked to epilepsy in FDA adverse event reports:
EPILEPSY has been reported as an adverse event in 888 FDA reports for OXCARBAZEPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPILEPSY accounts for approximately 1.5% of all adverse event reports for OXCARBAZEPINE, making it a notable side effect.
If you experience epilepsy while taking OXCARBAZEPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.